These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17692438)

  • 1. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults.
    Belshe RB; Newman FK; Wilkins K; Graham IL; Babusis E; Ewell M; Frey SE
    Vaccine; 2007 Sep; 25(37-38):6755-63. PubMed ID: 17692438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
    Chi RC; Rock MT; Neuzil KM
    Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
    Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
    Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.
    Coudeville L; Andre P; Bailleux F; Weber F; Plotkin S
    Hum Vaccin; 2010 Oct; 6(10):841-8. PubMed ID: 20930559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
    Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF
    Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
    Carter C; Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Chen GL; Patel SM; Winokur P; Belshe R; Dekker CL; Graham BS; Ledgerwood JE;
    PLoS One; 2019; 14(9):e0222178. PubMed ID: 31532789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
    Levin Y; Kochba E; Shukarev G; Rusch S; Herrera-Taracena G; van Damme P
    Vaccine; 2016 Oct; 34(44):5262-5272. PubMed ID: 27667332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.
    Atmar RL; Keitel WA; Cate TR; Munoz FM; Ruben F; Couch RB
    Vaccine; 2007 Jul; 25(29):5367-73. PubMed ID: 17559990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
    N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.
    Patel SM; Atmar RL; El Sahly HM; Cate TR; Keitel WA
    Vaccine; 2010 Apr; 28(17):3025-9. PubMed ID: 19931380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Leung MK; You JH
    Vaccine; 2016 May; 34(22):2469-76. PubMed ID: 27079928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients.
    Baluch A; Humar A; Eurich D; Egli A; Liacini A; Hoschler K; Campbell P; Berka N; Urschel S; Wilson L; Kumar D
    Am J Transplant; 2013 Apr; 13(4):1026-1033. PubMed ID: 23406320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial.
    Arakane R; Nakatani H; Fujisaki E; Takahama A; Ishida K; Yoshiike M; Nakayama T; Takeshita F
    Vaccine; 2015 Nov; 33(46):6340-50. PubMed ID: 26431983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.